Ken Garber. Show Affiliations »
Abstract
Entities: Disease
Mesh: See more » Adenocarcinoma/drug therapyAdenocarcinoma/metabolismAdenocarcinoma/mortalityAdenocarcinoma/pathologyAlbumins/administration & dosageAlbumins/pharmacologyAnimalsAntineoplastic Agents/pharmacologyAntineoplastic Agents/therapeutic useAntineoplastic Combined Chemotherapy Protocols/therapeutic useClinical Trials as TopicDeoxycytidine/administration & dosageDeoxycytidine/analogs & derivativesDisease-Free SurvivalErlotinib HydrochlorideHedgehog Proteins/drug effectsHedgehog Proteins/metabolismHumansOff-Label UseOsteonectin/metabolismPaclitaxel/administration & dosagePaclitaxel/pharmacologyPancreatic Neoplasms/drug therapyPancreatic Neoplasms/metabolismPancreatic Neoplasms/mortalityPancreatic Neoplasms/pathologyQuinazolines/administration & dosageSignal Transduction/drug effectsSurvival AnalysisUnited States/epidemiology
Substances: See more » 130-nm albumin-bound paclitaxelAlbuminsAntineoplastic AgentsHedgehog ProteinsOsteonectinQuinazolinesDeoxycytidinegemcitabineErlotinib HydrochloridePaclitaxel
Year: 2010 PMID: 20339135 DOI: 10.1093/jnci/djq113
Source DB: PubMed Journal: J Natl Cancer Inst ISSN: 0027-8874 Impact factor: 13.506